RU2021139886A - METHODS OF TREATMENT AND/OR PREVENTION OF PSORIASIS - Google Patents

Claims (31)

1. A method for treating and/or preventing psoriasis, comprising administering to a subject in need thereof a therapeutically effective amount of KX-01:

, or a pharmaceutically acceptable salt thereof. 2. The method of claim 1 wherein KX-01 is administered to the affected area of the subject at a dose of about 0.1 mg to about 10 mg, about 0.2 mg to about 5 mg, or about 0.5 mg to about 2.5 mg. 3. The method of claim 1, wherein KX-01 is administered to the affected area of the subject at a dose of about 0.2 mg, about 0.3 mg, about 0.4 mg, about 0.5 mg, about 0.6 mg, about 0.7 mg, about 0.8 mg, about 0.9 mg, about 1 mg, about 1.1 mg, about 1.2 mg, about 1.3 mg, about 1.4 mg, about 1.5 mg, about 1.6 mg, about 1.7 mg, about 1.8 mg, about 1.9 mg, about 2.0 mg, about 2.1 mg, about 2.2 mg, about 2.3 mg, about 2.4 mg, about 2.5 mg, about 2.6 mg, about 2.7 mg, about 2.8 mg, about 2.9 mg, about 3 mg, about 4 mg, or about 5 mg. 4. The method of claim 1 wherein KX-01 is administered to the affected area of the subject at a dose of about 0.0003 mg/cm ² to about 10 mg/cm ² , about 0.001 mg/cm ² to about 0.4 mg /cm ² , from about 0.005 mg/cm ² to about 0.1 mg/cm ² , from about 0.005 mg/cm ² to about 0.02 mg/cm ² or from about 0.025 mg/cm ² to about 0.1 mg/ ^cm2 . 5. The method of claim 1, wherein KX-01 is administered to the affected area of the subject at a dose of about 0.001 mg/cm ² , about 0.002 mg/cm ² , about 0.003 mg/cm ² , about 0.004 mg/cm ² cm ² , about 0.005 mg/cm ² , about 0.006 mg/cm ² , about 0.007 mg/cm ² , about 0.008 mg/cm 2 , about 0.009 mg/cm ² , about 0.01 mg/ ^{cm 2 ,} about 0.02 mg / cm ² , about 0.03 mg/cm ² , about 0.04 mg/cm ² , about 0.05 mg/cm ² , about 0.06 mg/cm ² , about 0.07 mg/cm ² , about 0.08 mg/cm ² , about 0.09 mg/cm ² , about 0.1 mg/cm ² , about 0.15 mg/cm ² , about 0.2 mg/cm ² , about 0.25 mg/cm cm ² , about 0.3 mg/cm ² , about 0.35 mg/cm ² or about 0.4 mg/cm ² . 6. The method of claim 2, wherein the affected area is from about 0.01 cm²up to about 300 cm², from about 1 cm²up to about 200 cm², from about 1 cm²up to about 100 cm², from about 1 cm²up to about 75 cm², from about 1 cm²up to about 50 cm², from about 1 cm²up to about 25 cm², from about 10 cm²up to about 200 cm², from about 10 cm²up to about 100 cm², from about 10 cm²up to about 75 cm²from about 10 cm²up to about 50 cm², from about 10 cm²up to about 25 cm², from about 25 cm²up to about 200 cm², from about 25 cm²up to about 100 cm², from about 25 cm²up to about 75 cm²or from about 25 cm²up to about 50 cm², from about 25 cm²up to about 90 cm², from about 25 cm²up to about 80 cm² or from about 25 cm²up to about 70 cm², from about 25 cm²up to about 60 cm², from about 25 cm²up to about 40 cm²or from about 25 cm²up to about 30 cm². 7. The method according to claim 2, in which the affected area is about 25 cm ² , about 30 cm ² , about 35 cm ² , about 40 cm ² , about 45 cm ² , about 50 cm ² , about 55 cm ² , about 60 cm ² , about 65 cm ² , about 70 cm ² , about 75 cm ² , about 80 cm ² , about 85 cm ² , about 90 cm ² , about 95 cm ² , or about 100 cm ² . 8. The method of claim 2 wherein the affected area is skin. 9. The method of claim 1 wherein KX-01 is administered once a week, once every three days, once every two days, once a day, twice a day, three times a day, or four times a day . 10. The method according to p. 1, in which KX-01 is administered for 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20 or 21 days. 11. The method of claim 1 wherein KX-01 is administered for 1, 2, 3, 4 or 5 days. 12. The method of claim 1 wherein KX-01 is administered on 1, 2, 3, 4, 5, or 6 days per week. 13. The method of claim 1 wherein KX-01 is administered once or twice a day continuously for more than one day per week followed by discontinuation for the remainder of the week. 14. The method of claim. 1, in which KX-01 is administered once or twice a day every other day, every three days, every four days, every five days, every six days or every seven days. 15. The method of claim 1 wherein KX-01 is administered once or twice a day for two consecutive days every three days, every four days, every five days, every six days, or every seven days. 16. The method of claim 1 wherein KX-01 is administered once or twice a day for three consecutive days every four days, every five days, every six days, or every seven days. 17. The method of claim 1, wherein KX-01 is administered once or twice a day for four consecutive days, every five days, every six days, or every seven days. 18. The method according to p. 1, in which KX-01 is administered until the psoriasis is completely cured. 19. The method of claim 1 wherein KX-01 is administered topically. 20. The method of claim 1 wherein administering KX-01 reduces the number and/or severity of local skin reactions or other adverse side effects, or the number of subjects experiencing local skin reactions or other adverse side effects compared to other methods. psoriasis treatment. 21. A compound for use in the treatment or prevention of psoriasis, comprising administering to a subject in need thereof a therapeutically effective amount of KX-01:

or a pharmaceutically acceptable salt thereof. 22. The use of a compound for the manufacture of a medicament for the treatment or prevention of psoriasis, comprising administering to a subject in need thereof a therapeutically effective amount of KX-01:

or a pharmaceutically acceptable salt thereof. 23. Use of a compound for the treatment or prevention of psoriasis, comprising administering to a subject in need thereof a therapeutically effective amount of KX-01:

or a pharmaceutically acceptable salt thereof.